Literature DB >> 11576751

Systemic adenosine infusions alleviated neuropathic pain.

Eva Gyllenhammar1, Lars-Olof Nordfors.   

Abstract

A 15-year-old boy suffering from a degenerative neurometabolic disorder was treated in a palliative home care unit. Opioid administered by continuous intravenous infusion gave excellent relief from headache, muscle pain and pain from renal calculi. He continued to complain of burning pain in response to tactile stimuli. A prior quantitative sensory test had shown changes in sensation. Intravenous adenosine (ADO) infusions were given weekly. After 5 weeks of infusions, there was no recurrence of pain between treatments. ADO infusions were continued for 7 months without any side effects or signs of tolerance to the drug. There are indications that ADO may play a role as a modulator of neuropathic and nociceptive pain. In this case with pronounced allodynia, our interpretation is that neuropathic mechanisms were responsible and that ADO infusions played an important role in controlling pain.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11576751     DOI: 10.1016/S0304-3959(01)00346-3

Source DB:  PubMed          Journal:  Pain        ISSN: 0304-3959            Impact factor:   6.961


  6 in total

1.  A3 adenosine receptor agonist attenuates neuropathic pain by suppressing activation of microglia and convergence of nociceptive inputs in the spinal dorsal horn.

Authors:  Ryuji Terayama; Mitsuyasu Tabata; Kotaro Maruhama; Seiji Iida
Journal:  Exp Brain Res       Date:  2018-09-11       Impact factor: 1.972

2.  [Adenosine for treatment of ischemic pain in thromboangiitis obliterans. A case report].

Authors:  Philip M Lang; D Irnich
Journal:  Schmerz       Date:  2007-06       Impact factor: 1.107

Review 3.  Neuropathic pain in children: Special considerations.

Authors:  Gary A Walco; Robert H Dworkin; Elliot J Krane; Alyssa A LeBel; Rolf-Detlef Treede
Journal:  Mayo Clin Proc       Date:  2010-03       Impact factor: 7.616

Review 4.  Clinical application of adenosine and ATP for pain control.

Authors:  Masakazu Hayashida; Ken-ichi Fukuda; Atsuo Fukunaga
Journal:  J Anesth       Date:  2005       Impact factor: 2.078

5.  Where do you want to spend your last days of life? Low concordance between preferred and actual site of death among hospitalized adults.

Authors:  Stacy Fischer; Sung-Joon Min; Lilia Cervantes; Jean Kutner
Journal:  J Hosp Med       Date:  2013-02-25       Impact factor: 2.960

6.  Pain-relieving effects of intravenous ATP in chronic intractable orofacial pain: an open-label study.

Authors:  Ken-Ichi Fukuda; Masakazu Hayashida; Atsuo Fukunaga; Masataka Kasahara; Yoshihiko Koukita; Tatsuya Ichinohe; Yuzuru Kaneko
Journal:  J Anesth       Date:  2007-01-30       Impact factor: 2.078

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.